Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... than a fifth of their body weight. The phase 3b STEP UP trial in more than 1,400 patients compared ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

Last week, Novo Nordisk released headline results from the STEP UP Phase 3b trial in the global STEP program. When evaluating the effects of treatment if all people adhered to treatment from a ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Statistically, your risk for cancer goes up from the very first sip of alcohol. However, what’s lost in this messaging is how ...